Tissue Regenix – 2022 results, is it “achieving strong commercial traction”?
Previously writing on regenerative medical device group Tissue Regenix (TRX), I noted argues distribution agreement ‘delight’. How’s that balance sheet now?. The group has now announced results for the 2022 calendar year, arguing they with it “having delivered on its strategy for growth whilst achieving strong commercial traction”. What does that actually mean financially though?
- By Steve Moore
- 2023-03-21 13:02:00